H-1337 Ophthalmic Solution Phase 1/2

Summary

The study will evaluate the safety, tolerability, and preliminary efficacy of three concentrations of H-1337 and vehicle administered twice daily in a parallel group, double-masked design for 28 days of dosing in patients with elevated intraocular pressure (IOP).

Timeline

Start

2018-03-15

Primary completion

2018-08-15

Completion

2018-08-15

Publications

• Hartman PJ, Cooke DL, Hsu HH, Stewart J, Sumi K, Yoshida Y, Hidaka H, Novack GD. Phase Ⅰ/Ⅱ, Double-Masked, Randomized, Vehicle-Controlled Study of H-1337 Ophthalmic Solution for Glaucoma and Ocular Hypertension. Ophthalmol Glaucoma. 2023 Mar-Apr;6(2):198-205. doi: 10.1016/j.ogla.2022.08.015. Epub 2022 Aug 31.

Drugs

Indications